Syntara Ltd Total Assets

Latest as of June 2025: AU$21.44 Million AUD ≈ $15.17 Million USD

Syntara Ltd total assets. Based on the latest financial reports, Syntara Ltd (SNT) holds total assets worth AU$21.44 Million AUD (≈ $15.17 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SNT company net worth for the company's overall valuation and market capitalisation.

Total Assets of Syntara Ltd (2003–2025)

Total assets of Syntara Ltd from 2003 to 2025. This chart illustrates how Syntara Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Syntara Ltd for real-time trading data and today's change.

Syntara Ltd - Asset Composition Analysis

Syntara Ltd Total Assets Breakdown (June 2025)

Syntara Ltd total assets breakdown as of June 2025. Syntara Ltd's total assets of AU$21.44 Million consist of 97.8% current assets and 2.2% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 70.3%
Accounts Receivable AU$5.66 Million 26.4%
Inventory AU$0.00 0.0%
Property, Plant & Equipment AU$180.00K 0.8%
Intangible Assets AU$149.00K 0.7%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2003–2025)

This chart illustrates how Syntara Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Syntara Ltd (SNT) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Syntara Ltd's current assets represent 97.8% of total assets in 2025, an increase from 90.1% in 2003.
  • Cash Position: Cash and equivalents constituted 70.3% of total assets in 2025, down from 89.6% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2003.
  • Asset Diversification: The largest asset category is accounts receivable at 26.4% of total assets.

Syntara Ltd Competitors by Total Assets

Key competitors of Syntara Ltd based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
Ajanta Pharma Limited
NSE:AJANTPHARM
India Rs56.72 Billion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
China CN¥9.54 Billion
Porton Fine Chemicals Ltd
SHE:300363
China CN¥8.58 Billion
Jubilant Pharmova Limited
NSE:JUBLPHARMA
India Rs135.21 Billion

Syntara Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.93 1.79 3.59
Quick Ratio 3.93 1.79 3.20
Cash Ratio 0.00 0.00 0.00
Working Capital AU$15.63 Million AU$4.32 Million AU$17.67 Million

Syntara Ltd - Advanced Valuation Insights

This section examines the relationship between Syntara Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.26
Latest Market Cap to Assets Ratio 0.97
Asset Growth Rate (YoY) 106.6%
Total Assets AU$21.44 Million
Market Capitalization $20.80 Million USD

Valuation Analysis

Near Book Valuation: The market values Syntara Ltd's assets close to their book value (0.97x), suggesting investors view the company's assets at approximately fair value.

Rapid Asset Growth: Syntara Ltd's assets grew by 106.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Syntara Ltd (2003–2025)

The table below shows the annual total assets of Syntara Ltd from 2003 to 2025.

Year Total Assets Change
2025-06-30 AU$21.44 Million
≈ $15.17 Million
+106.56%
2024-06-30 AU$10.38 Million
≈ $7.35 Million
-56.79%
2023-06-30 AU$24.03 Million
≈ $17.00 Million
-4.61%
2022-06-30 AU$25.19 Million
≈ $17.82 Million
-25.02%
2021-06-30 AU$33.59 Million
≈ $23.77 Million
-5.16%
2020-06-30 AU$35.42 Million
≈ $25.06 Million
-32.76%
2019-06-30 AU$52.67 Million
≈ $37.27 Million
+5.13%
2018-06-30 AU$50.10 Million
≈ $35.45 Million
+10.26%
2017-06-30 AU$45.43 Million
≈ $32.15 Million
-30.80%
2016-06-30 AU$65.65 Million
≈ $46.45 Million
-20.48%
2015-06-30 AU$82.56 Million
≈ $58.42 Million
+23.69%
2014-06-30 AU$66.75 Million
≈ $47.23 Million
-40.55%
2013-06-30 AU$112.28 Million
≈ $79.45 Million
-14.75%
2012-06-30 AU$131.70 Million
≈ $93.19 Million
+39.26%
2011-06-30 AU$94.57 Million
≈ $66.92 Million
-32.82%
2010-06-30 AU$140.77 Million
≈ $99.60 Million
-14.16%
2009-06-30 AU$164.00 Million
≈ $116.04 Million
+31.15%
2008-06-30 AU$125.05 Million
≈ $88.48 Million
+51.30%
2007-06-30 AU$82.65 Million
≈ $58.48 Million
-20.73%
2006-06-30 AU$104.27 Million
≈ $73.78 Million
+174.84%
2005-06-30 AU$37.94 Million
≈ $26.84 Million
+34.24%
2004-06-30 AU$28.26 Million
≈ $20.00 Million
-5.15%
2003-06-30 AU$29.79 Million
≈ $21.08 Million
--

About Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$20.80 Million
AU$29.39 Million AUD
Market Cap Rank
#24788 Global
#1009 in Australia
Share Price
AU$0.02
Change (1 day)
+0.00%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more